The Members’ General Meeting, held to coincide with the Society’s 16th Congress which took place on 24 and 25 November, approved the appointment.
The University of Pennsylvania professor and pioneer in developing cancer therapies using T cells covered the history, current state, and future chal1
The Hospital Clínic-IDIBAPS has developed the first CAR T-cell therapy in Europe to treat multiple myeloma, the second most common type of blood canc1
Interview with Dr. Manel Juan, head of the Immunology Service
The Spanish Agency of Medicines and Medical Devices (AEMPS) has approved CAR-T ARI-0001, developed by Hospital Clínic, as and advanced therapy drug o1
In just a few months, the coronavirus has gone from being completely unknown to being the focus of countless scientific investigations around the wor1
Immuneel Therapeutics Private Limited (Immuneel) today announced that it has entered into a multi-asset collaboration and licensing agreement with Ho1
Hospital Clínic de Barcelona-IDIBAPS and Cellnex have today signed an agreement to launch a multicentre research project that will allow better under1
Hospital Clínic – IDIBAPS (Barcelona) has founded Gyala Therapeutics, a new spin-off company focused on developing new CAR-T therapies for treating h1
The latest advance in the field of immune therapies against cancer are the active and targeted CAR therapies. This treatment consists of obtaining th1
